Abstract:Increased neuropeptide Y (NPY) expression occurred in the glucocorticoid-induced osteoporotic skeleton. NPY knockout mice exhibited a minor response to the glucocorticoid-mediated exacerbation of bone accretion and fatty marrow pathogenesis. NPY deletion restored SITR1 signaling and enhanced PPARγ ubiquitination of bone tissue, an alternative strategy for ameliorating glucocorticoid-induced skeletal deterioration.IntroductionGlucocorticoid excess is observed to worsen the pathogenesis of osteoporosis and fatty marrow. This study was undertaken to investigate the contribution of neuropeptide Y (NPY) to glucocorticoid-induced bone loss and marrow adiposity.MethodsNPY knockout and wild-type mice were administered methylprednisolone for four consecutive weeks. Bone mineral density, microarchitecture, and calcein-labeled mineral acquisition were quantified by μCT, dual energy X-ray absorptiometry, and histomorphometry. Expression of osteogenic and adipogenic markers and acetylation states of PPARγ were detected by RT-quantitative PCR, immunoprecipitation, and immunoblotting.ResultsHigh NPY levels were associated with glucocorticoid-induced trabecular bone deterioration and marrow fat accumulation. Mice lacking NPY had high bone mass concomitant with spacious trabecular and cortical bone microstructure. NPY deletion shielded skeletal tissues from the glucocorticoid-induced impediment of bone mass, trabecular morphometric characteristics, mineral accretion activity, and fatty marrow development. Ex vivo, NPY deficiency sustained osteogenic differentiation capacity and curtailed the glucocorticoid-mediated escalation of adipocyte formation reactions of primary bone-marrow mesenchymal cells. NPY deletion appeared to modulate Y1 and Y2 receptors, sirtuin 1, ERK, and p38 signaling pathways, an effect that facilitated hypoacetylation and ubiquitination of adipogenic transcription factor PPARγ in the skeletal tissues exposed to glucocorticoid stress.ConclusionsNPY mediates the glucocorticoid-induced disturbance of mineral accretion and marrow adipogenesis through post-translational modification of PPARγ. This study brings a new molecular insight into the disintegration of adipogenic and osteogenic activities within glucocorticoid-mediated osteoporotic skeletons. Control of NPY is an alternative strategy to ameliorate glucocorticoid-induced bone destruction and fatty marrow.

The Role of NPY in the Regulation of Bone Metabolism

The NPY System and its Neural and Neuroendocrine Regulation of Bone

Neuropeptide Y1 receptor antagonist promotes osteoporosis and microdamage repair and enhances osteogenic differentiation of bone marrow stem cells via cAMP/PKA/CREB pathway

Neuropeptide Y regulates osteocyte phenotype and function through AHNAK-Smad signalling

Neuromodulation of Bone: Role of Different Peptides and Their Interactions (Review)

Endocrine role of bone in the regulation of energy metabolism

Update on the Role of Neuropeptide Y and Other Related Factors in Breast Cancer and Osteoporosis

Neuropeptide Y mediates glucocorticoid-induced osteoporosis and marrow adiposity in mice

Neural regulation of bone remodeling: Identifying novel neural molecules and pathways between brain and bone

he roles of the sympathetic nervous system in osteoporotic diseases : review of experimental and clinical studies

The Role of Nervous System in Adaptive Response of Bone to Mechanical Loading

Neuropeptide Y stimulates osteoblastic differentiation and VEGF expression of bone marrow mesenchymal stem cells related to canonical Wnt signaling activating in vitro

Physiological and Therapeutic Roles of Neuropeptide Y on Biological Functions

The Role of Substance P in the Regulation of Bone and Cartilage Metabolic Activity

Neuropeptide Y‐Mediated Gut Microbiota Alterations Aggravate Postmenopausal Osteoporosis

Nuclear Receptor Regulation of Osteoclast and Bone Remodeling

Bone Injury and Repair Trigger Central and Peripheral NPY Neuronal Pathways

The roles of the sympathetic nervous system in osteoporotic diseases: A review of experimental and clinical studies.

Substance P and its receptors in bone metabolism.

Emerging roles of nerve‐bone axis in modulating skeletal system

The Role of XBP1 in bone metabolism